66
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan

, , , , , , , , , , , , , , & show all
Pages 725-732 | Published online: 08 Mar 2018

Figures & data

Table 1 Patient demographics and baseline characteristics

Figure 1 Mean PANSS total score up to week 24.

Notes: Progressive decrease in the mean PANSS total score in patients with schizophrenia who switched to paliperidone extended release (ER) from baseline to week 24. ITT, n = 297, *p < 0.0001 vs baseline.
Abbreviations: ITT, intention to treat; PANSS, Positive and Negative Syndrome Scale.
Figure 1 Mean PANSS total score up to week 24.

Table 2 Mean PANSS Marder factor scores from baseline to week 24

Table 3 Mean PSP scale, GAF scale, and CGI-S scores from baseline to week 24

Figure 2 Mean PANSS total score and CGI-S score for patients in medical centers and psychiatric hospitals.

Notes: Mean Positive and Negative Syndrome Scale (PANSS) total score and mean Clinical Global Impression-Severity (CGI-S) score in patients with schizophrenia who switched to paliperidone extended release (ER) grouped by facility type (medical center or psychiatric hospital) at baseline and week 24. Mean scores significantly decreased from baseline only in patients treated at medical centers.
Figure 2 Mean PANSS total score and CGI-S score for patients in medical centers and psychiatric hospitals.

Table 4 Baseline characteristics of patients with schizophrenia treated at medical centers versus psychiatric hospitals

Table 5 Incidence of AEs with oral paliperidone extended release treatment in all patients

Figure 3 Paliperidone ER dose distribution for patients in medical centers and psychiatric hospitals.

Note: Differences in distribution of dose of paliperidone extended release (ER) administered to patients with schizophrenia who switched from an other therapy, by facility type (medical center or psychiatric hospital), from baseline to week 24.
Figure 3 Paliperidone ER dose distribution for patients in medical centers and psychiatric hospitals.